Acute Myeloid Leukemia Clinical Trials

Acute Myeloid Leukemia (AML) is a life-threatening form of leukemia characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

The understanding of AML has evolved significantly over the last few decades. Recent years have seen a shift towards more targeted therapies, driven by deeper molecular and genetic insights.

iNGENū's team of experienced researchers and clinicians specializes in designing and conducting innovative studies. Leveraging enhanced trial design and comprehensive patient-centric strategies, we are committed to accelerating the development of new treatments for Acute Myeloid Leukemia.


Roughly

20k

new cases of AML are diagnosed annually in the United States

 

 



The median age of diagnosis for AML is

68

years old

 


The 5-year survival rate for AML is around

28%

varying based on age and other factors


Our clinical team has over

120

years of combined clinical trial experience

 

Download Our Paper

Fill out this form to download our white paper on how to overcome the biggest obstacles in conducting an acute myeloid leukemia clinical trial.

iNGENu_Acute_Myeloid_Leukemia_Clinical_Trials

In light of the impact AML has on individuals and society as a whole, continued research and awareness efforts are crucial to improve diagnosis, treatment, and ultimately, patients' quality of life.

The development of clinical trial protocols that meet FDA approval standards is crucial for the success of new AML treatments.